CDEK by Data4ThePeople

Sign in Sign up

← All organizations

Repligen Corporation

For profitContributed to NME

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Sep 9, 2022

Timeline

1980s

Jul 1, 1981
Repligen Corporation— Founded

2010s

Jun 27, 2017
Spectrum Pharmaceuticals— Acquired

2020s

Sep 9, 2022
eflapegrastim— NDA Organization
Sep 9, 2022
eflapegrastim— NDA Secondary Org

Drugs by trial phase (79 distinct, 113 trials)

Phase 3 (1 own, 20 via acquisition)

Phase 2 (1 own, 42 via acquisition)

Phase 1 (2 own, 13 via acquisition)

Indications

Studied for

Marketed drugs (1)

eflapegrastim

Subsidiaries (1 direct, 4 total across the full acquisition tree)

Recent trials (12)

NCT01371240CollaboratorEarly Phase 1Jun 1, 2011
NCT00812058Lead sponsorPhase 2Nov 1, 2008
NCT00660335Lead sponsorPhase 3Mar 1, 2008
NCT00660335Study directorPhase 3Mar 1, 2008
NCT00322764Lead sponsorPhase 2Mar 1, 2006
NCT00322764Study directorPhase 2Mar 1, 2006
NCT00235274CollaboratorPhase 2Nov 1, 2005
NCT00216294CollaboratorPhase 2Feb 1, 2005
NCT00060515Lead sponsorPhase 1May 7, 2003
NCT00076934CollaboratorPhase 1Jan 1, 2003
NCT00036244Lead sponsorPhase 3Apr 1, 2002
NCT00036231Lead sponsorPhase 3Apr 1, 2002

Details

Founded: Waltham, MA, US Jul 1, 1981
First NDA: Sep 9, 2022
Last known activity: Sep 9, 2022